Form 4: Hologic CEO Stephen Macmillan Executes Stock Option and Sells Shares Under 10b5-1 Plan

Hologic's CEO, Stephen Macmillan, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On July 17, 2024, Stephen Macmillan, the Chairman, President, and CEO of Hologic Inc., executed a transaction involving Hologic's common stock.
• Macmillan exercised 3,672 non-qualified stock options at a price of $26.21 per share.
• Simultaneously, Macmillan sold 3,672 shares of common stock at a weighted average price of $80.126 per share, with prices ranging from $80.00 to $80.29.
• These transactions were executed under an existing Rule 10b5-1 trading plan adopted on August 30, 2023, to exercise and sell expiring stock options.
• Following these transactions, Macmillan directly owns 1,157,562 shares of Hologic common stock and indirectly owns 1,146,829 shares through the MacMillan Family Trust.
• Macmillan also directly owns 44,039 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-arranged plan, suggesting no immediate cause for alarm or excessive optimism. The CEO is selling a small portion of their holdings.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
• The disclosure is transparent, providing details on the number of shares, prices, and the nature of the transactions.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, although it is part of a pre-arranged plan.

Risks

• While the 10b5-1 plan mitigates insider trading concerns, significant sales by executives can sometimes signal a lack of confidence in the company's future performance, although this is not necessarily the case here.

Industry Context

Executive stock transactions are common and closely monitored in the healthcare industry. The use of 10b5-1 plans is a standard practice to allow insiders to sell shares without raising concerns about insider trading.

Comparison to Industry Standards

• Executive compensation practices, including stock options and restricted stock units, are common across the medical device and diagnostics industry.
• Companies like Abbott Laboratories, Medtronic, and Danaher also utilize similar equity-based compensation plans for their executives.
• The use of 10b5-1 trading plans is a standard practice among publicly traded companies to facilitate orderly sales of stock by insiders.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on their perception of executive stock sales.
• Employees may be indirectly affected by any changes in investor sentiment.

Key Dates